Adagrasib Solid Pharmaceutical Compositions for Treating Cancer
Summary
The USPTO has published a new patent application (US20260083679A1) detailing solid pharmaceutical compositions containing adagrasib for treating cancer. The application, filed on December 3, 2025, includes methods for manufacturing these compositions and treating cancer.
What changed
This document is a new patent application published by the USPTO, specifically application US20260083679A1, titled 'Adagrasib Solid Pharmaceutical Compositions for Treating Cancer'. It details pharmaceutical compositions in solid form comprising adagrasib, intended for oral dosage to treat cancer, along with manufacturing methods and treatment protocols. The application was filed on December 3, 2025, by inventors Cletus Nunes, Mehrdad Kheiripour, and Monika Gavireddi.
As this is a patent application, it does not impose immediate compliance obligations or deadlines on regulated entities. However, it signifies potential future intellectual property rights related to adagrasib-based cancer treatments. Companies involved in the development, manufacturing, or marketing of adagrasib or similar oncology drugs should monitor this patent application for potential licensing opportunities or to assess freedom to operate in this therapeutic area.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ADAGRASIB SOLID PHARMACEUTICAL COMPOSITIONS
Application US20260083679A1 Kind: A1 Mar 26, 2026
Inventors
Cletus Nunes, Mehrdad Kheiripour, Monika Gavireddi
Abstract
Pharmaceutical compositions in solid form comprising adagrasib, suitable for oral dosage to treat subjects having cancer; as well as methods of manufacturing the compositions, and methods of treating cancer.
CPC Classifications
A61K 9/2054 A61K 9/0053 A61K 9/2009 A61K 9/2013 A61K 9/2018 A61K 9/2027 A61K 9/28 A61K 31/519
Filing Date
2025-12-03
Application No.
19407221
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.